Eton Pharmaceuticals, Inc.ETON stock score: 63/100
$61.36 · -1.02% · Scored Nov 19, 2026
- Technical
- 65
- Fundamental
- 63
- News
- —
The reading
Eton Pharmaceuticals (ETON) scores 63 out of 100, which reads neutral, higher than 85% of Healthcare stocks and 86% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 63, technicals 65.
Among the fundamentals, Earnings Estimates at 100 and Earnings Growth (Quarterly) at 100 score highest, while Earnings Growth (5-Year) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 66 and contrarian oscillators 39 — a split worth reading before trusting the technical total.
Since Aug 23, 2026 the composite has ranged from 55 to 64, and it is up 1 point over the period.
About Eton Pharmaceuticals
Eton Pharmaceuticals (ETON) is a U.S. pharmaceutical company that acquires, develops and sells treatments for rare diseases, with a focus on products for children and patients with endocrine and metabolic conditions. Its products include Alkindi Sprinkle and Khindivi, two forms of hydrocortisone for adrenal insufficiency, Increlex for severe primary insulin-like growth factor deficiency, and Desmoda, an oral solution of desmopressin. It has also added Hemangeol for infantile hemangioma and U.S. rights to Impavido, a treatment for a parasitic infection, along with other rare disease products. Eton often focuses on dosage forms that make medicines easier for young patients to take. The company sells mainly through specialty pharmacies and supports patients through its own access program. It earns money from product sales and seeks to grow by acquiring or licensing approved and late-stage products.
Eton competes with generic versions of older medicines, compounded formulations and therapies from larger drugmakers in each disease area. Its edge rests on a small, focused sales team that reaches specialists in rare pediatric diseases, a growing portfolio that shares the same commercial infrastructure and its ability to buy products that larger companies set aside. Investors who follow ETON stock tend to watch product sales growth and the number of patients on its adrenal therapies. Progress on label expansions for Khindivi and Increlex is closely followed. New product acquisitions and launches, gross margin, operating costs and debt are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward ETON’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
63Pulling it up
Earnings estimates score evaluates analyst projections for future profitability.
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
How the latest quarter's revenue compares with the average of the last four, plus a bonus for steady quarterly revenue.
Holding it back
5-year earnings growth evaluates long-term profit trajectory and consistency.
Price-to-Book ratio compares market value to book value.
Net income growth from the prior fiscal year to the latest.
37 weighted scorers; 2 had no data today and are left out rather than counted as zero.
Technical · daily
63Pulling it up
Rate of Change measures the percentage change in price over a specified period.
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
- EMA 200100
Exponential Moving Average (200-period) is a crucial long-term trend indicator that reacts faster than SMA-200.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
SPY SMA 20 measures the S&P 500 (SPY) position relative to its 20-period moving average.
SPY SMA 50 tracks the S&P 500 (SPY) position relative to its 50-period moving average.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 40 | 1 |
| Daily | 63 | 3 |
| Weekly | 70 | 2 |
| Monthly | 73 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 63 |
| Nov 18, 2026 | 63 |
| Nov 17, 2026 | 63 |
| Nov 16, 2026 | 64 |
| Nov 15, 2026 | 64 |
| Nov 14, 2026 | 64 |
| Nov 13, 2026 | 64 |
| Nov 12, 2026 | 64 |
| Nov 11, 2026 | 62 |
| Nov 10, 2026 | 62 |
| Nov 8, 2026 | 63 |
| Nov 7, 2026 | 62 |
| Nov 6, 2026 | 61 |
| Nov 5, 2026 | 57 |
| Nov 4, 2026 | 56 |
| Nov 3, 2026 | 57 |
| Nov 2, 2026 | 57 |
| Nov 1, 2026 | 58 |
| Oct 30, 2026 | 58 |
| Oct 29, 2026 | 59 |
| Oct 28, 2026 | 58 |
| Oct 27, 2026 | 57 |
| Oct 26, 2026 | 56 |
| Oct 25, 2026 | 55 |
| Oct 24, 2026 | 55 |
| Oct 23, 2026 | 56 |
| Oct 22, 2026 | 56 |
| Oct 21, 2026 | 55 |
| Oct 20, 2026 | 56 |
| Oct 19, 2026 | 55 |
| Oct 18, 2026 | 55 |
| Oct 17, 2026 | 55 |
| Oct 16, 2026 | 55 |
| Oct 15, 2026 | 55 |
| Oct 14, 2026 | 56 |
| Oct 13, 2026 | 56 |
| Oct 12, 2026 | 58 |
| Oct 11, 2026 | 59 |
| Oct 10, 2026 | 59 |
| Oct 9, 2026 | 58 |
| Oct 8, 2026 | 57 |
| Oct 7, 2026 | 57 |
| Oct 6, 2026 | 57 |
| Oct 5, 2026 | 58 |
| Oct 4, 2026 | 58 |
| Oct 3, 2026 | 58 |
| Oct 2, 2026 | 58 |
| Oct 1, 2026 | 55 |
| Sep 30, 2026 | 55 |
| Sep 29, 2026 | 60 |
| Sep 28, 2026 | 59 |
| Sep 27, 2026 | 59 |
| Sep 26, 2026 | 59 |
| Sep 25, 2026 | 59 |
| Sep 24, 2026 | 60 |
| Sep 23, 2026 | 59 |
| Sep 22, 2026 | 59 |
| Sep 21, 2026 | 57 |
| Sep 20, 2026 | 57 |
| Sep 19, 2026 | 57 |
| Sep 18, 2026 | 57 |
| Sep 17, 2026 | 58 |
| Sep 16, 2026 | 58 |
| Sep 15, 2026 | 56 |
| Sep 14, 2026 | 58 |
| Sep 13, 2026 | 58 |
| Sep 12, 2026 | 58 |
| Sep 11, 2026 | 58 |
| Sep 10, 2026 | 57 |
| Sep 9, 2026 | 58 |
| Sep 8, 2026 | 60 |
| Sep 7, 2026 | 58 |
| Sep 6, 2026 | 58 |
| Sep 5, 2026 | 58 |
| Sep 4, 2026 | 58 |
| Sep 3, 2026 | 59 |
| Sep 2, 2026 | 61 |
| Sep 1, 2026 | 60 |
| Aug 31, 2026 | 60 |
| Aug 30, 2026 | 59 |
| Aug 29, 2026 | 59 |
| Aug 28, 2026 | 59 |
| Aug 27, 2026 | 60 |
| Aug 26, 2026 | 60 |
| Aug 25, 2026 | 60 |
| Aug 24, 2026 | 62 |
| Aug 23, 2026 | 62 |
Key facts
- Market cap
- $1.8B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Beta
- 0.83
- Risk grade (1–10)
- 8
- Next earnings
- Nov 5, 2026
Specialty & Generic Drug Manufacturers peers
| Company | Market cap | Score |
|---|---|---|
| PRGO Perrigo Company | $2.2B | 48 |
| RGC Regencell Bioscience Holdings | $2.2B | 24 |
| BCRX BioCryst Pharmaceuticals | $1.9B | 72 |
| ANIP ANI Pharmaceuticals | $1.6B | 67 |
| ALVO Alvotech | $1.5B | 55 |
| PCRX Pacira BioSciences | $1.5B | 65 |
All Specialty & Generic Drug Manufacturers stocks, highest-scored first
Questions
What is ETON's stock rating today?
ETON scores 63/100 (Neutral) as of Nov 19, 2026: technical 65, fundamental 63. Scores are recomputed every night.
What does Eton Pharmaceuticals do?
Eton Pharmaceuticals (ETON) is a U.S. pharmaceutical company that acquires, develops and sells treatments for rare diseases, with a focus on products for children and patients with endocrine and metabolic conditions.
Is ETON stock a buy?
The score is not a buy or sell recommendation. A 63 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the ETON score calculated?
99 weighted scorers feed it today: 37 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/eton/"><img src="https://stocksscores.com/stocks/eton/badge.svg" alt="ETON stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/eton/)